Five Prime Therapeutics to Host Research & Development Day on December 8, 2016
November 30, 2016 16:05 ET
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 30, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
Five Prime to Present Preclinical Data at 2016 SITC Annual Meeting Demonstrating Potent Anti-Tumor Activity with Novel Tetravalent Anti-GITR Antibody
November 11, 2016 07:00 ET
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
Five Prime Announces Third Quarter 2016 Results and Provides Business Update
November 03, 2016 16:05 ET
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
Five Prime to Present Preclinical Data at 2016 SITC Annual Meeting For Novel Tetravalent Anti-GITR Antibody
November 03, 2016 09:00 ET
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
Five Prime Therapeutics to Present at the 25th Annual Credit Suisse Healthcare Conference
October 26, 2016 16:05 ET
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 26, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing...
Five Prime Therapeutics to Announce Third Quarter 2016 Financial Results and Host Conference Call on November 3
October 20, 2016 16:05 ET
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 20, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
Five Prime Therapeutics Advances into Phase 1b Portion of Trial Evaluating the Immunotherapy Combination of Cabiralizumab (FPA008) and OPDIVO (nivolumab) in Multiple Tumor Types
October 04, 2016 09:00 ET
|
Five Prime Therapeutics, Inc.
Phase 1a/1b trial on track to enroll approximately 280 patientsPhase 1b portion of the trial will assess safety, tolerability and initial efficacy in multiple tumor types SOUTH SAN FRANCISCO,...
Five Prime Therapeutics to Present at the LEERINK Partners Rare Disease & Immuno-Oncology Roundtable
September 22, 2016 16:05 ET
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 22, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
Five Prime Therapeutics Announces Key Executive Promotions
September 20, 2016 16:41 ET
|
Five Prime Therapeutics, Inc.
Aron Knickerbocker promoted to Chief Operating OfficerFrancis Sarena promoted to Chief Strategy Officer Luis Borges, Ph.D., promoted to Senior Vice President, Research SOUTH SAN FRANCISCO,...
Five Prime Therapeutics to Present at the Morgan Stanley Global Healthcare Conference
September 06, 2016 16:05 ET
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...